Natco Pharma

₹975.4 6.3 | 0.6%

WEBSITE BSE:524816 NSE : NATCO PHARM 10 May, 16:01

Market Cap ₹17469 Cr.

Stock P/E 13.7

P/B 3.2

Current Price ₹975.4

Book Value ₹ 307.4

Face Value 2

52W High ₹1107.9

Dividend Yield 0.56%

52W Low ₹ 609.6

Edit Ratio

Natco Pharma Research see more...

Overview Inc. Year: 1981Industry: Pharmaceuticals & Drugs

Natco Pharma Ltd is a pharmaceutical company. The Company is engaged in developing, production and advertising finished dosage formulations (FDF) and active pharmaceutical elements (APIs). The Company's segments include energetic prescription drugs factor, finished dosage formulations, job works, pharmacy and others. The Company's product categories consist of Domestic Formulations, International Formulations, API's and Blockbusters. The Company's merchandise include Thioplan, Anastronat, Capnat, Fulvenat, Kabanat, Natdox-LP, Alphalan, Bandrone, Bendit, Clokeran, Lenalid, Rapact, Temonat, X-Trant, Glatimer, Hepcinat, Lansoprazole, Letrozole, Granisetron, Rizatriptan IR, Imatinib, Salmeterol Xinafoate, Sertraline Form I, Natdac, Natzold, Tigi, Alprazolam, Chloroquine Phosphate, Ibandronate Sodium Monohydrate, Pantoprazole Sodium Sesquihydrate, Ondansetron Hydrochloride (Injectable Grade), Daclatasvir and Glatiramer Acetate. The Company manufactures over 20 merchandise underneath contract.

Natco Pharma Share Price

New

Volume

Price

Price: NSE50 DMA200 DMAVolume

Quarterly Price

Quarterly Monthly

Show Value Show %

Peer Comparison

Natco Pharma Quarterly Results

#(Fig in Cr.)	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023
Net Sales	377	561	597	885	432	493	898	1141	1031	759
Other Income	38	30	14	34	21	21	29	20	29	37
Total Income	415	591	611	919	453	513	927	1160	1061	796
Total Expenditure	307	459	615	489	337	387	559	613	573	491
Operating Profit	109	132	-5	430	116	127	368	548	487	305
Interest	4	5	7	4	4	4	3	4	4	5
Depreciation	35	36	38	40	42	42	41	44	44	44
Exceptional Income / Expenses	0	0	0	0	0	0	0	0	0	0
Profit Before Tax	70	91	-50	386	70	81	324	500	440	256
Provision for Tax	5	11	1	65	14	19	49	80	71	44
Profit After Tax	65	80	-51	320	57	62	276	420	369	213
Adjustments	0	0	0	0	0	0	0	0	0	0
Profit After Adjustments	65	80	-51	320	57	62	276	420	369	213
Adjusted Earnings Per Share	3.6	4.4	-2.8	17.6	3.1	3.4	15.1	23.5	20.6	11.9

Natco Pharma Profit & Loss

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	TTM
Net Sales	661	739	730	1042	2020	2185	2095	1915	2052	1945	2707	3829
Other Income	12	17	14	10	14	40	130	107	106	99	129	115
Total Income	673	756	745	1052	2034	2225	2225	2022	2158	2044	2836	3944
Total Expenditure	511	560	524	777	1337	1256	1300	1332	1448	1681	1795	2236
Operating Profit	162	196	220	275	697	969	925	690	710	363	1040	1708
Interest	26	37	32	23	19	15	19	22	13	18	15	16
Depreciation	22	30	47	51	54	66	81	100	117	143	164	173
Exceptional Income / Expenses	-12	0	-15	0	0	0	0	0	0	0	0	0
Profit Before Tax	102	129	126	202	624	887	825	569	580	202	862	1520
Provision for Tax	36	31	2	48	140	192	182	111	137	32	147	244
Profit After Tax	66	98	125	154	485	695	642	458	442	170	715	1278
Adjustments	6	5	10	4	1	1	2	3	-2	0	0	0
Profit After Adjustments	72	103	135	157	486	696	644	461	441	170	715	1278
Adjusted Earnings Per Share	4.6	6.2	8.1	9	27.9	37.7	35.3	25.3	24.2	9.3	39.2	71.1

Growth Rates

#	1 Year	3 Year	5 Year	10 Year
Sales CAGR	39%	12%	4%	15%
Operating Profit CAGR	187%	15%	1%	20%
PAT CAGR	321%	16%	1%	27%

#	1 Year	3 Year	5 Year	10 Year
Share Price CAGR	50%	1%	12%	20%
ROE Average	16%	10%	13%	17%
ROCE Average	18%	12%	15%	20%

Natco Pharma Balance Sheet

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Shareholder's Funds	534	726	846	1296	1649	3072	3489	3774	4122	4264	4874
Minority's Interest	11	7	5	5	4	4	2	11	2	0	0
Borrowings	138	95	97	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	54	55	22	28	38	47	83	118	143	135	101
Total Current Liabilities	345	312	414	493	627	592	729	685	526	710	683
Total Liabilities	1080	1196	1384	1822	2318	3715	4303	4588	4792	5109	5657
Fixed Assets	583	645	710	710	833	1019	1227	1584	2023	2312	2427
Other Non-Current Assets	167	183	191	275	397	566	729	678	424	311	230
Total Current Assets	330	368	483	837	1087	2131	2347	2326	2345	2487	3000
Total Assets	1080	1196	1384	1822	2318	3715	4303	4588	4792	5109	5657

Natco Pharma Cash Flow

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Opening Cash & Cash Equivalents	35	10	10	-164	24	24	22	28	20	26	111
Cash Flow from Operating Activities	61	144	93	112	346	464	669	417	299	47	849
Cash Flow from Investing Activities	-107	-109	-115	-176	-299	-1116	-612	-167	-103	-5	-477
Cash Flow from Financing Activities	26	-35	29	154	-48	651	-51	-251	-186	35	-363
Net Cash Inflow / Outflow	-20	-0	7	91	-1	-1	6	-1	10	76	9
Closing Cash & Cash Equivalent	10	10	12	-74	24	22	28	20	26	111	132

Natco Pharma Ratios

#	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Earnings Per Share (Rs)	4.58	6.21	8.1	9.03	27.85	37.73	35.31	25.32	24.16	9.32	39.19
CEPS(Rs)	5.61	7.77	10.35	11.75	30.91	41.27	39.64	30.65	30.65	17.13	48.17
DPS(Rs)	0.8	1	1	1.25	6.75	8.25	6.25	6.75	5.25	4.5	5.5
Book NAV/Share(Rs)	34.01	43.9	50.91	73.91	93.63	165.22	189.49	206.04	224.88	233.44	267.06
Core EBITDA Margin(%)	22.44	24.08	27.72	24.59	33.09	42.16	34.79	28.31	28.97	11.89	31.64
EBIT Margin(%)	19.25	22.24	21.27	20.78	31.13	40.99	36.94	28.68	28.45	9.92	30.42
Pre Tax Margin(%)	15.31	17.32	17.01	18.66	30.24	40.29	36.1	27.63	27.81	9.12	29.91
PAT Margin (%)	9.86	13.17	16.81	14.22	23.48	31.57	28.12	22.26	21.23	7.67	24.83
Cash Profit Margin (%)	13.17	17.26	23.14	18.92	26.12	34.58	31.66	27.11	26.84	14.1	30.51
ROA(%)	6.64	8.62	9.69	9.58	23.43	23.05	16.02	10.3	9.43	3.43	13.29
ROE(%)	13.08	15.58	15.9	14.41	33.21	29.7	19.75	12.71	11.27	4.06	15.66
ROCE(%)	16.04	18.02	14.89	17.49	39.21	35.28	23.71	14.82	13.99	4.86	18.06
Receivable days	61.3	60.9	76.4	76.72	65.12	92.22	91.36	93.77	84.44	85.1	93.53
Inventory Days	70.04	80.17	98.47	97.54	62.41	65.25	77.28	96.38	118.77	128.47	95.32
Payable days	148.98	168.74	252.46	270.38	163.98	236.08	266.65	243.26	151.52	106.38	133.18
PER(x)	18.73	25.66	52.09	45.64	30.41	19.99	16.19	19.99	34.16	81.3	14.38
Price/Book(x)	2.52	3.63	8.29	5.58	9.05	4.57	3.02	2.46	3.67	3.24	2.11
Dividend Yield(%)	0.93	0.63	0.24	0.3	0.8	1.09	1.09	1.33	0.64	0.59	0.98
EV/Net Sales(x)	2.53	3.88	10.01	6.94	7.41	6.36	5.03	4.94	7.33	7.21	3.66
EV/Core EBITDA(x)	10.31	14.62	33.18	26.3	21.46	14.35	11.39	13.71	21.19	38.67	9.52
Net Sales Growth(%)	26.12	11.86	-1.14	42.69	93.82	8.15	-4.13	-8.57	7.16	-5.23	39.2
EBIT Growth(%)	25.39	28.74	-4.51	41.91	186.5	40.4	-6.49	-30.07	0.46	-62.91	298.54
PAT Growth(%)	12.68	48.91	27.35	22.94	215.69	43.37	-7.59	-28.69	-3.43	-61.57	320.76
EPS Growth(%)	19.71	35.6	30.39	11.45	208.47	35.49	-6.43	-28.3	-4.58	-61.44	320.76
Debt/Equity(x)	0.63	0.33	0.37	0.09	0.14	0.06	0.11	0.08	0.06	0.09	0.03
Current Ratio(x)	0.96	1.18	1.17	1.7	1.74	3.6	3.22	3.39	4.46	3.5	4.39
Quick Ratio(x)	0.54	0.61	0.65	0.97	1.18	2.86	2.5	2.63	3.04	2.49	3.35
Interest Cover(x)	4.89	4.52	4.99	9.8	34.75	58.61	43.73	27.45	44.58	12.42	60.44
Total Debt/Mcap(x)	0.25	0.09	0.04	0.02	0.02	0.01	0.04	0.03	0.02	0.03	0.02

Natco Pharma Shareholding Pattern

#	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Promoter	48.86	48.81	48.8	48.8	48.82	48.84	49.76	49.71	49.71	49.71
FII	12.23	11.94	11.65	11.67	11.72	11.91	11.02	12.82	13.72	16.14
DII	18.11	16.15	15.29	14.3	14.93	15.37	15.15	14.01	11.25	9.7
Public	20.8	23.1	24.25	25.23	24.53	23.87	24.07	23.46	25.32	24.46
Others	0	0	0	0	0	0	0	0	0	0
Total	100	100	100	100	100	100	100	100	100	100

#	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Promoter	8.91	8.91	8.91	8.91	8.91	8.91	8.91	8.9	8.9	8.9
FII	2.23	2.18	2.13	2.13	2.14	2.17	1.97	2.3	2.46	2.89
DII	3.3	2.95	2.79	2.61	2.73	2.81	2.71	2.51	2.01	1.74
Public	3.79	4.22	4.43	4.61	4.48	4.36	4.31	4.2	4.54	4.38
Others	0	0	0	0	0	0	0	0	0	0
Total	18.24	18.25	18.26	18.26	18.26	18.25	17.91	17.91	17.91	17.91

Pros

Company is almost debt free.

Cons

Promoter holding is low: 49.71%.
Company has a low return on equity of 10% over the last 3 years.
Debtor days have increased from 106.38 to 133.18days.
Stock is trading at 3.2 times its book value.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Natco Pharma News

IPO

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Natco Pharma

Add Watchlist

Natco Pharma Research see more...

Overview Inc. Year: 1981Industry: Pharmaceuticals & Drugs

Natco Pharma Share Price

Alert Data

Quarterly Price

Peer Comparison

Natco Pharma Quarterly Results

Natco Pharma Profit & Loss

Growth Rates

Natco Pharma Balance Sheet

Natco Pharma Cash Flow

Natco Pharma Ratios

Natco Pharma Shareholding Pattern

Natco Pharma News

IPO

Stocx: India's #1 Marketplace to Find Your Winning Stock

Please Login!

Error!